Angiotensin receptor-neprilysin inhibitors: comprehensive review and implications in hypertension treatment
The effectiveness of this treatment has been highlighted in several clinical trials, including one study where participants experienced an average weight loss of 15.2% of their body weight, compared to 2.6% in the placebo group
Clinical trials involving retatrutide in the UK are subject to oversight under the Medicines for Human Use (Clinical Trials) Regulations 2004 and require MHRA clinical trial authorisation
T2D patients with severe renal impairment are not eligible for SGLT2 inhibitors, and GLP-1RAs could be an important therapeutic option for these patients
Queen on hormone optimization or menopause care, GLP-1 therapy can be an excellent complement to personalized nutrition, bioidentical hormone therapy (when appropriate), and functional nutrition guidance
Renoprotective Effects of Small Interfering RNA Targeting Liver Angiotensinogen in Experimental Chronic Kidney Disease